ReviewSubstance abuse2008
Pharmacotherapy of methamphetamine addiction: an update.
Review in Substance abuse, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Methamphetamine-Related Disorders.Deutsches Arzteblatt international · 2017Guideline
- Efficacy of psychostimulant drugs for amphetamine abuse or dependence.The Cochrane database of systematic reviews · 2013Pooled it
- Effects of mindfulness yoga intervention on physical function, anxiety, inflammatory response, and relapse intention in methamphetamine addicts: a 24-week randomized controlled trial.Frontiers in public health · 2026Trial
- A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.Drug and alcohol dependence · 2018Trial
- Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.Drug and alcohol dependence · 2018Trial
- Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence.BMC psychiatry · 2016Trial
- The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Trial
- Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2015Trial
- Transcriptome profiling and pathway analysis of genes expressed differentially in participants with or without a positive response to topiramate treatment for methamphetamine addiction.BMC medical genomics · 2014Trial
- Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.Addiction (Abingdon, England) · 2014Trial
- Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.Psychopharmacology · 2014Trial
- Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers.Progress in neuro-psychopharmacology & biological psychiatry · 2012Trial
- Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance.Psychopharmacology · 2011Trial
- Profiling gene alterations in striatonigral neurons associated with incubation of methamphetamine craving by cholera toxin subunit B-based fluorescence-activated cell sorting.Frontiers in cellular neuroscience · 2025Article
- Europinidin Attenuates Methamphetamine-induced Learning and Memory Impairments and Hippocampal Alterations in Rodents: Based on Molecular Docking through a Mechanism of Neuromodulatory Cytokines/ Caspases-3/ CREB/BDNF Pathway.Current medicinal chemistry · 2025Article
- The Effectiveness of Mindfulness in the Treatment of Methamphetamine Addiction Symptoms: Does Neuroplasticity Play a Role?Brain sciences · 2024Review
- Sub-chronic nicotine exposure influences methamphetamine self-administration and dopamine overflow in a sex-and genotype-dependent manner in humanizedFrontiers in pharmacology · 2024Article
- Deletion of VGLUT2 in midbrain dopamine neurons attenuates dopamine and glutamate responses to methamphetamine in mice.Pharmacology, biochemistry, and behavior · 2021Article
- β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors PossiblyFrontiers in pharmacology · 2021Article
- Methamphetamine-Induced Neuronal Damage: Neurotoxicity and Neuroinflammation.Biomolecules & therapeutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
Abstract
Methamphetamine dependence is a serious public health problem worldwide for which there are no approved pharmacological treatments. Psychotherapy is still the mainstay of treatment; however, relapse rates are high. The search for effective pharmacological treatment has intensified in the last decade. This review will highlight progress in pharmacological interventions to treat methamphetamine dependence as well as explore new pharmacological targets. Published data from clinical trials for stimulant addiction were searched using PubMed and summarized, as well as highlights from a recent symposium on methamphetamine pharmacotherapy presented at the ISAM 2006 meeting, including interim analysis data from an ongoing D-amphetamine study in Australia. Early pilot data are encouraging for administering D-amphetamine and methylphenidate as treatment for heavy amphetamine users. Abilify at 15 mg/day dose increased amphetamine use in an outpatient pilot study. Sertraline, ondansetron, baclofen, tyrosine, and imipramine were ineffective in proof-of-concept studies. Development of pharmacotherapy for methamphetamine dependence is still in an early stage. Data suggesting D-amphetamine and methylphenidate as effective pharmacotherapy for methamphetamine addiction will need to be confirmed by larger trials. Preclinical data suggest that use of GVG, CB1 antagonist, and lobeline are also promising therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.